The Chronic Diseases Clinic of Ifakara (CDCI)—Establishing a Model Clinic for Chronic Care Delivery in Rural Sub-Saharan Africa

Maja Weisser 1,2,3,4,*, Martin Rohacek 2,3,4, Robert Ndege 4,5,*, Ezekiel Luoga 4,5, Andrew Katende 4,5,*, Getrud J. Mollel 4,5, Winfrid Gingo 5, Fiona Vanobberghen 2,3, Daniel H. Paris 2,3, Christoph Hatz 2,3, Manuel Battegay 1,2,* and on behalf of the KIULARCO Study Group †

1 Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, 4031 Basel, Switzerland
2 University of Basel, 4001 Basel, Switzerland
3 Swiss Tropical and Public Health Institute, 4123 Allschwil, Switzerland
4 Ifakara Health Institute, Ifakara P.O. Box 53, Tanzania
5 St. Francis Referral Hospital, Ifakara P.O. Box 73, Tanzania
* Correspondence: maja.weisser@usb.ch (M.W.); manuel.battegay@usb.ch (M.B.);
Tel.: +41-328-67-42 (M.W.); +41-61-265-50-53 (M.B.)
† Collaborators of the KIULARCO study group are shown in the Acknowledgements.

Abstract: The rollout of antiretroviral drugs in sub-Saharan Africa to address the huge health impact of the HIV pandemic has been one of the largest projects undertaken in medical history and is an unprecedented medical success story. However, the path has been and still is characterized by many far reaching implementational challenges. Here, we report on the building and maintaining of a role model clinic in Ifakara, rural Southwestern Tanzania, within a collaborative project to support HIV services within the national program, training for staff and integrated research to better understand local needs and improve patients’ outcomes.

Keywords: chronic care; rural sub-Saharan Africa; HIV; Tuberculosis; non-communicable diseases

1. Introduction

Since the late eighties, the HIV pandemic has affected the African continent most tragically and disproportionally compared to other parts of the world. HIV/AIDS remains a major threat to the population. Eastern and Southern Africa continue to have the highest burden of people living with HIV (PLHIV)—20.6 million or 54% in 2021—despite tremendous progress in the reduction of new HIV infections by 61% since 2010 [1]. Adolescent girls remain at highest risk for new HIV infections with three times higher risks compared to males of the same age group.

According to the UNAIDS report 2022, in Tanzania, the HIV/AIDS incidence has further decreased to 0.96/100,000 (54,000 new infections in 2021). The number of AIDS-related deaths has halved since 2010 but remains unacceptably high with 29,000 people dying from AIDS in 2021. Currently, 88% of people know their HIV status (1st 95% of the UNAIDS cascade goals); 86% of PLHIV are in care (2nd 95%) and 83% are virally suppressed (3rd 95%) [1].

The implementation of integrated HIV care programs in rural settings remains challenging due to lack of trained staff and availability of specialized services [2–4]. Here, we describe a collaborative project to build up one of the first rural clinics to deliver HIV care services in support of the National AIDS Control Program of Tanzania, integration of mother and child care, TB services and services for non-communicable diseases as a model clinic for chronic disease care.
2. The HIV Pandemic in 2000—Implementation of a Rural Care and Treatment Center

After the Durban AIDS conference in 2000 with recognition of the huge gap in HIV programs in Africa, international collaborations started to tackle the HIV pandemic. In 2003 the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) was funded as the most important funding agency to implement HIV programs on a large scale in sub-Saharan Africa. While this allowed financing of the drug supply, implementation of HIV care programs remained challenging due to lack of trained healthcare staff, logistics and a healthcare system not equipped for chronic care. In 2003, during this period, the Chronic Diseases Clinic of Ifakara (CDCI) in rural Tanzania was founded as a joint collaboration between the St. Francis Referral Hospital in Ifakara, the Ifakara Health Institute in Tanzania, the Swiss Tropical and Public Health Institute and the University Hospital Basel in Switzerland. From the very beginning the concept was to establish a setting with preventive and clinical services at its center, and training and clinical research as equally important pillars to ensure the highest quality of care and sustainability through capacity building of staff and analysis of patients’ outcomes and specific needs of this rural area.

After a long period where only counselling of PLHIV was possible and 1.5 years of organizational work, building up clinical and laboratory structures and teams, the first patient was able to be treated on 1 May 2005. Since then, the CDCI has uninterruptedly delivered services to patients of Ifakara and the surrounding districts in the Kilombero Valley, serving as a referral site for very sick patients for a growing catchment area of now more than 1 million inhabitants.

3. Structure and Procedures of the Clinic

The focus of the CDCI is on HIV testing, enrolment into care, screening for opportunistic infections, and same-day initiation of antiretroviral treatment (“test and treat”). CDCI provides care for in- and outpatients with an HIV and/or tuberculosis infection according to the Tanzanian guidelines, collaborating closely with local implementing partners of national HIV programs, district and national governmental authorities (Figures 1 and 2). Key elements are integration of the CDCI into the outpatient department of the hospital to reduce stigmatization, close links with other services and specialists. Furthermore, the establishment of an electronic patient data system with standardized electronic questionnaires (Open Medical Record System, [www.openmrs.org](http://www.openmrs.org)) was central to allow simultaneous access for all collaborators in charge of patient services (clinicians, triage, registration, pharmacy, laboratory) contributing to a highly efficient workflow and systematic documentation for clinical and research purposes [2]. The system is continuously updated according to guideline changes and research necessities by a local statistics team with support for training and development from the partners.

Figure 1. Waiting area of the Chronic Diseases Clinic of Ifakara.
Currently, forty staff members employed at the CDCI by the different partners ensure continuous care for about 4200 patients under active care in the outpatient department and inpatients with HIV and/or tuberculosis. Nurses triage outpatients and direct them towards clinical consultations at least once yearly, or in the presence of new symptoms, to the pharmacist for drug refill or to counselling services if indicated. The viral suppression rate for those attending the CDCI is high at 92% [3]. Medical doctors are trained to assess patients with complex medical conditions and supervise clinical officers. Professional and lay counsellors support patients with psychosocial health issues, poor adherence to drugs, stigmatization and challenges to care for HIV-infected dependents.

To reduce attrition, we offer a bundle of interventions for newly diagnosed patients aiming to reduce stigmatization in a structured program, namely (a) one-to-one counselling by an HIV-positive lay person, (b) viewing of a locally made video, in which PLHIV talk about their experience, (c) offering group therapy during waiting times provided by HIV-positive lay counsellors and (d) assessment of stigma and depression during the first year [4].

4. Kilombero and Ulanga Antiretroviral Cohort (KIULARCO)

The KIULARCO is one of the biggest and longest standing cohorts of PLHIV in East Africa with more than 12,000 consenting PLHIV enrolled since 2005 (Figure 3). The long-term nature of the cohort—currently 17 years—and the large set of systematic clinical and laboratory data collected together with a large biobank make this cohort unique [2,5]. Based on its data and biobank important scientific manuscripts on treatment outcomes [3,6,7], mother to child transmission [8–10], comorbidities [11–17], mortality [5,6] and other aspects were published and helped to adjust HIV service delivery to better meet patients’ needs.
To ensure high-quality care, immunologic and virologic monitoring was established at an early time-point and allowed the site to become the referral hub in viral load and early infant DNA PCR testing for the four surrounding districts in the Kilombero valley, closely collaborating with the national AIDS control program. Resistance testing has been established for patients failing on antiretroviral treatment, which is central in the management of patients and helps to inform stakeholders of the national antiretroviral programs [3,18,19].

5. Integration of Services

Screening, diagnosis and management of tuberculosis—the most common comorbidity in HIV-infected patients—has been fully integrated in the CDCI. All patients are screened according to the Tuberculosis and Leprosy National Control Program (NTLP) guidelines. Implementation of screening questions, chest X-ray and real-time PCR (Xpert MTB/RIF) [20] led to an increase in case detection. Additionally, we have established sonography for assessment of extrapulmonary tuberculosis (EPTB) [21] (Figures 4 and 5).

Figure 4. Clinical evaluation of a patient in the wards.

Figure 5. Ultrasound-guided puncture of a liver abscess.

6. ‘One Stop Clinic’: Integration of Antenatal and Under-Five Clinic

A successful part of the clinic is a family-centered program, the “One Stop Clinic”, which was implemented in 2013 to improve services for HIV-infected pregnant and breastfeeding mothers together with their partners and children. Services are offered by one team to the whole family under the same roof, located at the Reproductive and Child Care Clinic of the hospital. With this program, mother-to-child transmission has reduced to below 2% [8,9] with no transmission among virally suppressed breastfeeding women [10]. Age-appropriate disclosure services are offered to children living with HIV and psychological
support to adolescents living with HIV is done by a trained counsellor until transition to adult HIV services is reached at the age of 19 years.

7. Non-Communicable Diseases

During long-term care of PLHIV, increasingly other comorbidities are recognized, importantly non-communicable diseases (NCDs) such as arterial hypertension [11], and other cardiovascular diseases, as well as cancer and chronic anaemia [12]. In 2021 a new heart and lung disease clinic was established in close proximity to the CDCI and the One Stop Clinic, sponsored by the Else Kröner Fresenius Foundation. This clinic offers specialized and chronic care for patients with heart and lung diseases such as, e.g., hypertensive heart diseases, valvular heart diseases, asthma, post-tuberculosis lung diseases and other pulmonary diseases. An important aspect is the creation of awareness on the importance of NCDs, which is addressed by regular outreach programs to the community, offering education, screening and referral for those with detected health issues.

8. Training

Every day, the first working hour is reserved for education and training of staff, including clinical case presentations, state of the art lectures on HIV and associated diseases, interdisciplinary discussion on patients with a high HIV viral load or sequencing results, and a journal club. Sessions are coordinated by a team member on a rotational basis, contributing to a continuous medical education and fostering clinical discussion among the team. Additionally, the CDCI aims to support trainings for Master and PhD programs and medical specialization.

9. Research

Many important research questions have already been answered through use of the prospective database of the KIULARCO Cohort [2,5] and it continues to provide a rich resource to address newly arising questions. Additionally, CDCI serves increasingly as a platform for clinical trials nested within the collaborative activities, such as a randomized controlled two center trial to study the added value of sonography in the management of patients with suspected extrapulmonary tuberculosis [22], the CoArtHA trial to identify the best antihypertensive drug strategy [23] or the GIVE-MOVE trial to analyze the impact of drug resistance testing in children and adolescents failing on first line treatment on the treatment outcome [24].

10. Conclusions and Perspectives

The platform for high-quality care, training and research is based on a longstanding and excellent collaboration between the key partners. A strong collaboration with national stakeholders enabled the CDCI to become a scalable model clinic for service delivery in rural sites. With the progress of antiretroviral drugs, “treatment as prevention” with “U=U”, i.e., “Undetectable equals Untransmittable”, care of utmost quality becomes increasingly important for patients and their beloved ones and will guide the future. The essence of the CDCI—good care for patients—continues to be the basis to tackle new developments, unforeseen challenges and to improve lives of people living with HIV.

Author Contributions: All authors contributed equally to this manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: The CDCI is funded by the National AIDS Control Program, the implementing partners (currently USAID Afya yangu), the Kanton Baselstadt, Switzerland, the Swiss Tropical and Public Health Institute and the University Hospital Basel.

Institutional Review Board Statement: The Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) as a part of the CDCI seeks yearly ethical approval with the local Institutional Review Board from the Ifakara Health Institute and on the national level from the National Institute of Medical Research.
Informed Consent Statement: Patients participating in the KIULARCO sign a informed consent form upon enrollment.

Data Availability Statement: Not applicable.

Acknowledgments: The authors wish to express their gratitude to all the staff involved since the creation of the Chronic Diseases Clinic Ifakara, colleagues from the St. Francis Referral Hospital, the Ifakara Health Institute and the Swiss Tropical and Public Health Institute, the University Hospital Basel and all who support the CDCI. We are equally grateful for the collaboration and funding from the National AIDS Control Program, the implementing partners, e.g., USAID Afya yangu and the Canton Basel-Stadt for financial support over the last 17 years. The authors express their profound thanks to Marcel Tanner for his continuous support and commitment, without which the CDCI would not exist and we congratulate him from the bottom of our hearts on his 70th birthday. The Kilombero and Ulanga Antiretroviral Cohort study group (KIULARCO): Aneth V. Kalinjuma, Andrew Katende, Amiri Kayela, Namvua Kimera, Yassin Kisunga, Olivia Kitau, Bernard Kivuma, Thomas Klimkait, Juma Kupewa, Emil Letang, Ezekiel Luoga, Harry Mapesi, Honorati Masanja, Swalehe Masoud, Mohammed Mbaruku, Geoffrey Mbunda, Elisante Mchomvu, Sylakay Mlembe, Mengi Mkulila, Margareth Mkusa, Lina Mnunga, Alpha Mnjie, Dorcas K. Mnzava, Getrud J. Mollie, Lilian Moshi, Germaina Mossad, Erik Mossdorf, Dolores Mpundunga, Athuman Mwambo, Elizabeth Ntamatungiro, Eliza Ntamatungiro, Elizabeth Nyuri, James Okuma, Daniel H. Paris, Martin Rohacek, Aloyce Sambuta, Leila Samson, Elizabeth Senkoro, George Sigalla, Jamali B Siru, Marcel Stoeckle, Jenifa Tarimo, Victor Urio, Juerg Utzinger, Fiona Vanobberghen, Maja Weisser, John Wigay, Herieth Wilson, Lulu Wilson.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. UNAIDS. IN DANGER: UNAIDS Global AIDS Update 2022; License: CC BY-NC-SA 3.0 IGO; Joint United Nations Programme on HIV/AIDS: Geneva, Switzerland, 2022.
2. Letang, E.; Kalinjuma, A.V.; Glass, T.R.; Gamell, A.; Mapesi, H.; Sikalengo, G.R.; Luwanda, L.B.; Mnzava, D.; Ntamatungiro, A.J.; Ndaki, R.; et al. Cohort profile: The Kilombero and Ulanga Antiretroviral Cohort (KIULARCO)—A prospective HIV cohort in rural Tanzania. Swiss Med. Wkly. 2017, 147, w14485. [PubMed]
3. Ntamatungiro, A.J.; Muri, L.; Glass, T.R.; Erb, S.; Battegay, M.; Furrer, H.; Hatz, C.; Tanner, M.; Felger, I.; Klimkait, T.; et al. Strengthening HIV therapy and care in rural Tanzania affects rates of viral suppression. J. Antimicrob. Chemother. 2017, 72, 2069–2074. [CrossRef]
4. Magnolini, R.; Senkoro, E.; Vanobberghen, F.; Weisser, M. “Linkage to care” among people living with HIV—definition in the era of “universal test and treat” in a sub-Sahara African setting. Swiss Med. Wkly. 2021, 151, w20535. [CrossRef] [PubMed]
5. Vanobberghen, F.; Letang, E.; Gamell, A.; Mnzava, D.K.; Faini, D.; Luwanda, L.B.; Mapesi, H.; Mwambo, K.; Sikalengo, G.; Tanner, M.; et al. A decade of HIV care in rural Tanzania: Trends in clinical outcomes and impact of clinic optimisation in an open, prospective cohort. PLoS ONE 2017, 12, e0180983. [CrossRef] [PubMed]
6. Kalinjuma, A.V.; Glass, T.R.; Weisser, M.; Myeya, S.J.; Kasuga, B.; Kisung’a, Y.; Sikalengo, G.; Katende, A.; Battegay, M.; Vanobberghen, F.; et al. Prospective assessment of loss to follow-up: Incidence and associated factors in a cohort of HIV-positive adults in rural Tanzania. J. Int. AIDS Soc. 2020, 23, e25460. [CrossRef] [PubMed]
7. Vanobberghen, F.; Weisser, M.; Kasuga, B.; Katende, A.; Battegay, M.; Tanner, M.; Glass, T.R.; on behalf of the KIULARCO Study Group. Mortality in a Cohort of People Living with HIV in Rural Tanzania, Accounting for Unseen Mortality Among Those Lost to Follow-up. Am. J. Epidemiol. 2020, 190, 251–264. [CrossRef] [PubMed]
8. Gamell, A.; Glass, T.R.; Luwanda, L.B.; Mapesi, H.; Samson, L.; Mtoi, T.; Nyamtema, A.; Muri, L.; Ntamatungiro, A.; Tanner, M.; et al. Implementation and Operational Research: An Integrated and Comprehensive Service Delivery Model to Improve Pediatric and Maternal HIV Care in Rural Africa. J. Acquir. Immune Defic. Syndr. 2016, 73, e67–e75. [CrossRef]
9. Gamell, A.; Luwanda, L.B.; Kalinjuma, A.V.; Samson, L.; Ntamatungiro, A.J.; Weisser, M.; Gingo, W.; Tanner, M.; Hatz, C.; Letang, E.; et al. Prevention of mother-to-child transmission of HIV Option B+ cascade in rural Tanzania: The One Stop Clinic model. PLoS ONE 2017, 12, e0181096. [CrossRef]
10. Luoga, E.; Vanobberghen, F.; Bircher, R.; Nyuri, A.; Ntamatungiro, A.J.; Mnzava, D.; Mollel, G.J.; Letang, E.; Battegay, M.; Weisser, M.; et al. Brief Report: No HIV Transmission From Virally Suppressed Mothers During Breastfeeding in Rural Tanzania. J. Acquir. Immune Defic. Syndr. 2018, 79, e17–e20. [CrossRef]
11. Rodríguez-Arboli, E.; Mwamelo, K.; Kalinjuma, A.V.; Furrer, H.; Hatz, C.; Tanner, M.; Battegay, M.; Letang, E.; KIULARCO Study Group. Incidence and risk factors for hypertension among HIV patients in rural Tanzania—A prospective cohort study. *PLoS ONE* 2017, 12, e0172089.

12. Albrecht, S.; Franzek, F.C.; Mapesi, H.; Hatz, C.; Kalinjuma, A.V.; Glass, T.R.; Mnzava, D.; Letang, E.; Paris, D.H.; Battegay, M.; et al. Age-related comorbidities and mortality in people living with HIV in rural Tanzania. *AIDS* 2019, 33, 1031–1041. [CrossRef]

13. Mapesi, H.; Kalinjuma, A.V.; Ngerecha, A.; Franzek, F.; Hatz, C.; Tanner, M.; Mayr, M.; Furrer, H.; Battegay, M.; Letang, E.; et al. Prevalence and Evolution of Renal Impairment in People Living With HIV in Rural Tanzania. *Open Forum. Infect. Dis.* 2018, 5, ofy072. [CrossRef]

14. Mapesi, H.; Okuma, J.; Franzek, F.; Wilson, H.I.; Senkoro, E.; Byakuzana, T.; Ndege, R.; Vanobberghen, F.; Glass, T.R.; Battegay, M.; et al. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. *PLoS ONE* 2021, 16, e0261367. [CrossRef]

15. Franzek, F.C.; Ngwale, R.; Msongole, B.; Hamisi, M.; Abdul, O.; Henning, L.; Letang, E.; Mwaigomole, G.; Battegay, M.; Hatz, C.; et al. Viral hepatitis and rapid diagnostic test based screening for HBsAg in HIV-infected patients in rural Tanzania. *PLoS ONE* 2013, 8, e58468. [CrossRef]

16. Katende, A.; Mbwanji, G.; Faini, D.; Nyuri, A.; Kalinjuma, A.V.; Mnzava, D.; Hullsiek, K.H.; Rhein, J.; Weisser, M.; Meya, D.B.; et al. Short-course amphotericin B in addition to sertraline and fluconazole for treatment of HIV-associated cryptococcal meningitis in rural Tanzania. *Mycoses* 2019, 62, 1127–1132. [CrossRef]

17. Winter, A.; Letang, E.; Kalinjuma, A.V.; Kimera, N.; Ntamatungiro, A.; Glass, T.; Moradpour, D.; Sahli, R.; Le Gal, F.; Furrer, H.; et al. Absence of hepatitis delta infection in a large rural HIV cohort in Tanzania. *Int. J. Infect. Dis.* 2016, 46, 8–10. [CrossRef]

18. Mapesi, H.; Gupta, R.; Wilson, H.I.; Luwanda, L.B.; Battegay, M.; Furrer, H.; Hatz, C.; Tanner, M.; Felger, I.; et al. Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: An emerging public health concern. *AIDS* 2017, 31, 61–70.

19. Haraka, F.; Glass, T.R.; Sikalengo, G.; Gamell, A.; Nt amatungiro, A.; Hatz, C.; Tanner, M.; Furrer, H.; Battegay, M.; Letang, E. A Bundle of Services Increased Ascertainment of Tuberculosis among HIV-Infected Individuals Enrolled in a HIV Cohort in Rural Sub-Saharan Africa. *PLoS ONE* 2015, 10, e0123275. [CrossRef]

20. Ndege, R.; Weisser, M.; Elzi, L.; Diggelmann, F.; Bani, F.; Gingo, W.; Sikalengo, G.; Mapesi, H.; Mchomvu, E.; Kamwela, L.; et al. Sonography to Rule Out Tuberculosis in Sub-Saharan Africa: A Prospective Observational Study. *Open Forum. Infect. Dis.* 2019, 10, ozf154. [CrossRef]

21. Ndege, R.; Ngome, O.; Bani, F.; Temba, Y.; Wilson, H.; Vanobberghen, F.; Hella, J.; Gingo, W.; Sasamalo, M.; Mnzava, D.; et al. Ultrasound in managing extrapulmonary tuberculosis: A randomized controlled two-center study. *BMC Infect. Dis.* 2020, 20, 349. [CrossRef] [PubMed]

22. Mapesi, H.; Gupta, R.; Wilson, H.I.; Lukau, B.; Amstutz, A.; Lyimo, A.; Muhairwe, J.; Senkoro, E.; Byakuzana, T.; Mphunyane, M.; et al. The coArThA trial-identifying the most effective treatment strategies to control arterial hypertension in sub-Saharan Africa: Study protocol for a randomized controlled trial. *Trials* 2021, 22, 77. [CrossRef] [PubMed]

23. Brown, J.A.; Ringera, I.; Luoga, E.; Cheleboi, M.; Kimera, N.; Muhairwe, J.; Kayembe, B.P.; Molapo Hlasoa, M.; Kabundi, L.; Yav, C.W.D.; et al. Genotype-Informed Versus Empiric Management Of VirEmia (GIVE MOVE): Study protocol of an open-label randomised clinical trial in children and adolescents living with HIV in Lesotho and Tanzania. *BMC Infect. Dis.* 2020, 20, 773. [CrossRef] [PubMed]